GSK Wellbutrin XL joins IR and SR formulations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves GlaxoSmithKline's latest bupropion formulation, Wellbutrin XL, for treatment of major depressive disorder Aug. 28, shortly ahead of the agent's Sept. 3 user fee goal. The firm plans a mid-September launch of the extended-release norepinephrine/dopamine reuptake inhibitor; GSK licensed the once-daily formulation from Biovail. Timing of the approval provides GSK with a short time to try and convert patients from its twice-daily product, Wellbutrin SR, to XL before the SR product faces generic competition. Andrx indicated its intent to launch generic SR within the first few months of XL's launch. The generic firm is hoping that uptake of XL will be hindered by the absence of a comparison to SR in labeling; approved labeling only notes similar bioavailability of XL (300 mg once a day) to immediate release Wellbutrin (100 mg three times a day). GSK will likely position XL as offering an improved safety profile, with reduced seizures and sleeplessness...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.